Related Experiment Videos
Late evaluation of patients undergoing valve replacement with the Björk-Shiley prosthesis
Insights
The Björk-Shiley prosthesis demonstrated good long-term survival in 484 patients after heart valve replacement. Early diagnosis and treatment are crucial for improving outcomes in patients with severe heart conditions.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
Background:
- Heart valve replacement is a critical procedure for patients with severe valvular heart disease.
- The Björk-Shiley prosthesis was a significant development in prosthetic heart valves during the 1970s.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of the Björk-Shiley prosthesis in patients undergoing mitral, aortic, or combined valve replacement.
- To assess patient outcomes, including survival rates, thromboembolic events, and bleeding complications.
Main Methods:
- Analysis of 484 patients who received Björk-Shiley valve prostheses between 1970 and 1974.
- Long-term follow-up conducted on 435 patients (98.2%) for an average of 3.67 years.
- Actuarial survival analysis and assessment of complication rates.
Main Results:
- 80-85% of patients experienced noticeable improvement.
- Thromboembolic complications occurred in 6.9% of patients (1.5 emboli/1000 patient-months).
- Anticoagulant bleeding complications occurred in 6.4% of patients, with a late mortality rate of 15% and a 6-year survival of 79%.
Conclusions:
- The Björk-Shiley prosthesis showed acceptable long-term results for heart valve replacement during the study period.
- Preoperative New York Heart Association Functional Classification significantly impacted survival, with Class IV patients experiencing reduced outcomes.
- Emphasized the need for earlier diagnosis and treatment to enhance long-term survival in cardiac patients.
Abstract:
This study analyzes 484 patients who survived mitral, aortic, or mitral and aortic valve replacement using the Björk-Shiley prosthesis from January, 1970, through December 31, 1974. Long-term follow-up of 1 1/2 to 6 1/2 years (mean, 3.67 yr) was done on 435 patients (98.2%). Eighty to 85% of the patients have improved noticeably. Thromboembolic problems occurred in 6.9%, representing 1.5 emboli per 1,000 patient-months. Anticoagulant bleeding problems occurred in 6.4% of the patients; late mortality was 15%. Actuarial survival curves showed patients at risk to 6 years having a 79% chance of survival. The same analysis according to preoperative New York Heart Association Functional Classification showed a striking reduction in survival in class IV patients. The Björk-Shiley prosthesis is a good choice for valve replacement today. Earlier diagnosis and treatment are needed to obtain better long-term survival.